What factors affect prognosis for Pancreatic Cancer

Factors That Affect Prognosis for Pancreatic Cancer

Prognosis—the likely course and outcome of your disease—depends on several interconnected factors. Understanding these can help you have more informed conversations with your care team.

Stage of Disease at Diagnosis (Most Important)

According to the NCCN Guidelines for Pancreatic Cancer, the stage when cancer is discovered is one of the most critical factors:

• Early-stage disease (Stage 0-II): Cancers caught before spreading to distant organs have better outcomes because surgery may be possible
• Locally advanced (Stage III): Cancer has spread to nearby blood vessels but not distant organs
• Metastatic (Stage IV): Cancer has spread to distant organs like the liver or lungs—this significantly impacts prognosis

Key insight: As one expert notes, "outcomes largely depend on whether the cancer can be surgically removed or not, more than the stage of disease." Surgery remains the only potentially curative treatment.

Resectability (Can It Be Surgically Removed?)

This is perhaps THE most important prognostic factor:

• Resectable: Tumor can be completely removed → better outcomes
• Borderline resectable: Tumor touches major blood vessels; surgery is riskier
• Unresectable: Tumor is too close to or wrapped around vital structures → surgery not possible

Tumor Grade

Grade describes how abnormal cancer cells look under a microscope:

• Grade 1 (Low): Cells look almost normal; slower growth
• Grade 3-4 (High): Cells look very abnormal; more aggressive, faster growth and spread

Higher-grade tumors are associated with worse prognosis.

Genetic/Molecular Profile

Recent advances show that what mutations your cancer has matters significantly:

KRAS Mutations

• Found in approximately 87-90% of pancreatic cancers
• Associated with poor outcomes, but now targetable with newer drugs
• Presence of KRAS mutations was historically linked to worse progression-free survival

Homologous Repair Deficiency (HRD)

• Includes BRCA1, BRCA2, PALB2 mutations
• These patients may respond better to specific treatments (PARP inhibitors, chemotherapy)
• Can improve outcomes when matched with appropriate therapy

MTAP Deletion

• Found in 15-20% of pancreatic cancer patients
• Emerging treatment implications that may affect prognosis

CA 19-9 Tumor Marker

• Blood test measuring a protein released by cancer cells
• Higher levels generally indicate more aggressive disease
• Important note: About 10-15% of patients don't produce CA 19-9 (called "non-producers"), which may indicate different biology and potentially worse chemotherapy response

Response to Treatment

How well your cancer responds to initial chemotherapy is a strong prognostic indicator:

• Good response: Tumor shrinks significantly → better outcomes
• Poor response: Tumor doesn't shrink much → worse prognosis
• Circulating tumor DNA (ctDNA): Research shows patients with detectable genetic alterations in their blood had worse progression-free survival (6.2 months vs. 15.3 months for those without detectable alterations)

Overall Health & Performance Status

Your general health matters:

• Ability to tolerate aggressive chemotherapy
• Presence of other medical conditions
• Nutritional status (pancreatic cancer causes severe muscle/fat wasting in ~80% of patients)
• Management of side effects

Age

While not absolute, younger patients generally tolerate treatment better, though age alone isn't the determining factor.

Recent Positive Trend

There's encouraging news: According to recent data, the five-year survival rate for pancreatic cancer has increased to 13%, up from 6% just 10 years ago. This improvement is largely driven by:

• Earlier detection in some cases
• Better management of localized disease
• Emerging targeted therapies for specific mutations

---

Questions to Ask Your Oncologist

To understand YOUR specific prognosis:

1. "What is my cancer's stage, and what does that mean for my treatment options?"
2. "Has molecular profiling been done on my tumor? What mutations does my cancer have?"
3. "Is my cancer resectable, borderline resectable, or unresectable, and how does that affect my prognosis?"
4. "What is my CA 19-9 level, and what does it tell us about my cancer?"
5. "Based on all these factors, what is the expected progression-free and overall survival for someone in my situation?"
6. "Are there clinical trials available that match my tumor's molecular profile?"

---

Important Context: Prognosis is statistical—it describes what typically happens to groups of patients, not what will happen to you individually. Every patient is unique, and advances in treatment are happening rapidly. According to ASCO and NCCN guidelines, patients with pancreatic cancer should seek care at high-volume centers with multidisciplinary teams who can evaluate all these factors together and offer the most current treatment options.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.